Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants (PNIRS in VLBWI)

17. november 2026 oppdatert av: Lizelle Van Wyk, University of Stellenbosch

Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants: a Pilot Study

This study will look at whether a monitoring method called near-infrared spectroscopy (NIRS), can help assess lung disease in premature babies.

The main aim of this study is to describe lung oxygen levels measured by NIRS in premature babies with respiratory distress syndrome (RDS) during the first 72 hours after birth. The study will include babies born at or before 32 weeks of pregnancy who need continuous positive airway pressure (CPAP) for RDS. The study will also assess whether these lung oxygen measurements can help predict which babies will need surfactant treatment, and whether they can predict which babies may need more than one dose of surfactant.

The study will also compare lung NIRS measurements with other ways of assessing breathing problems, including lung ultrasound scores and oxygen-related measurements. In addition, the researchers will compare lung oxygen measurements with brain oxygen measurements. They will also look at whether surfactant treatment changes oxygen levels in the lungs and brain. Information from routine vital signs, such as heart rate, breathing rate, and oxygen saturation, will also be studied to see whether these measurements can help predict the need for surfactant.

Added to this researchers will look at the hemodynamics of surfactant administration by seeing how the heart and blood vessels react to surfactant administration

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

Aim: To determine pulmonary regional oxygen saturation (prSO2) in preterm infants (≤32 weeks) with respiratory distress syndrome (RDS) requiring continuous positive airway pressure (CPAP) with or without surfactant replacement therapy (SRT)

Objectives:

Primary: Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life. Secondary: (1) Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS, (2) Evaluate the ability of prSO2 to predict the need for repeat surfactant administration in preterm infants with RDS, (3) Determine correlation between prSO2, lung ultrasound (LUS) scores and oxygenation indices.

Tertiary: (1) Determine the correlation between prSO2 and cerebral oxygenation (crSO2), (2) Determine the effect of surfactant administration on prSO2 and crSO2, (3) longitudinal analyses of vital signs (HR, SpO2, NIRS, oxygenation indices) to predict SRT, (4) determine the hemodynamic effects of SRT (longitudinal correlation of NIRS, haemodynamic parameters)

This will be an investigator-initiated, prospective, observational trial.

Preterm infants born at a gestational age ≤ 32 weeks will be recruited from a single neonatal center, Tygerberg Hospital, Cape Town, South Africa.

All preterm infants ≤ 32 weeks and/ or ≤1800g will be eligible for enrollment

Study Procedures

Recruitment and enrollment processes Infants will be screened within the first 3 hours after birth. Infants meeting enrollment criteria will be placed on study monitoring devices upon arrival in the neonatal unit, if meeting eligibility criteria.

Randomization/ blinding No randomization will occur in this study. Blinding is not possible due to visible monitoring equipment. Treating clinicians will however be directed not to use the monitors for any decision-making regarding patient management.

Monitoring Devices

  1. Near-infrared spectroscopy will be performed using INVOS 5100c (Medtronics, Minneapolis, MN, USA) with 2 transducers, will be used that allows monitoring of 4 regions of interest. In this study 3 regional saturations will be monitored - pulmonary (left and right) and cerebral

    • Pulmonary NIRS - Pulmonary sensors will be placed in a horizontal position at the 4th intercostal space area (nipple line) on the left and right hemithorax
    • Cerebral NIRS - Cerebral sensor will be placed on the right of the forehead
  2. Vital sign monitoring: Synchronized vital signs (heart rate (HR), respiratory rate (RR), peripheral oxygen saturation (SpO2) (Nellcor) will be monitored using a multi-parameter monitor (Mindray UMEC15, Shenzhen, China).

  3. Non-invasive cardiac output monitoring: Haemodynamic monitoring will occur using the ICON Core from Osypka Medical. This provides non-invasive monitoring of numerous haemodynamic parameters, including cardiac output, stroke volume, systemic vascular resistance, cardiac contractility and thoracic fluid content. ICON sensors will be placed in standard positions on the forehead, neck arm and leg for monitoring.

Intervention procedures

1. Ultrasound:

  1. Lung ultrasound (LUS) will be performed after placement of the NIRS (within the first 6 hours of life) and daily. LUS will also be performed prior to any SRT. alculated. Video-clips will be stored and reviewed by blinded co-investigators.
  2. Cranial ultrasound (CUS) will be performed on day 1,2 and 3 to monitor for any intraventricular haemorrhage as well as to measure cerebral blood flow velocities, which may affect crSO2 values.
  3. Point-of-care echocardiography (POC-echo) will be performed to determine cardiac function, cardiac output, and the presence of a patent ductus arteriosus, size, flow velocity and pattern, which may affect prSO2 and crSO2 values. Standard echocardiography techniques will be used and will be performed daily on day 1,2 and 3 of life.

Trial duration

The trial will start enrolling 1 November 2026 or when all procedures have been completed. Trial will be completed when 100 participants have been recruited.

Discontinuation of study intervention

Monitoring of the infant will stop, and sensors will be removed if:

  • Requested by mother
  • Requested by treating clinician
  • Thoracic intervention required (e.g. intercostal drainage for pneumothorax)
  • Surgery required (e.g. laparotomy for focal intestinal perforation)
  • Sensors interfere with medical management

Withdrawal from study

At any time point the mother or treating clinician may request withdrawal of the infant from the study, for any reason, whether for personal choice (by the mother), safety considerations or administrative reasons. Monitoring of the infant will be stopped immediately, and no further data will be collected. However, the infant will remain in the study for data analyses and outcome and clinical measure collection, unless the mother specifically requests that their infant's data not be included. Withdrawal of the infant from the study, irrespective of reason, will not influence the continued management of the infant and they will continue to receive management as per protocols in the institution.

Duration of study participation

Study participation for each infant is:

  • Initiated within the first 3 hours of life
  • Monitoring until 72 hours after birth
  • Follow up from 72 hours until final discharge from hospital or in-hospital death.

Infants who are transferred to other institutions will be followed up for length of stay as well as neonatal respiratory complications (length of respiratory support, bronchopulmonary dysplasia, death)

Studietype

Observasjonsmessig

Registrering (Antatt)

100

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Cape Town, Sør-Afrika, 7530
        • Rekruttering
        • Tygerberg Hospital
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lizelle Van Wyk, PhD
        • Underetterforsker:
          • Pierre Goussard, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 måneder til 7 måneder (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

All preterm infants 27-32 weeks born at Tygerberg Hospital, Cape Town, South Africa will be elligible for enrollment

Beskrivelse

Inclusion Criteria:

  • Preterm infant ≤ 32 weeks gestational age and/ or birth weight ≤ 1800g
  • Infant diagnosed with respiratory distress syndrome requiring CPAP after birth
  • Infant born at the research institution

Exclusion Criteria:

  • Infants ≤ 26 weeks gestational age or <750g
  • Infants with other causes of respiratory distress
  • Infants with antenatal or postnatally diagnosed structural pulmonary abnormalities
  • Infants with known or suspected chromosomal abnormalities
  • Infants with other congenital structural abnormalities that may require surgery in the first 72 hours after birth
  • Infants with known or suspected congenital infections including congenital syphilis, cytomegalovirus or toxoplasmosis
  • Infants intubated after birth or requiring intubation and invasive ventilation immediately after birth
  • Infants with a 5-minute Apgar ≤ 5
  • Instillation of surfactant prior to enrollment
  • Infants not expected to survive the first 72 hours after birth

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
CPAP only

Infants receiving CPAP only

Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position

SRT

Infants receiving CPAP plus surfactant

Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
PRSO2 values
Tidsramme: 72 hours

Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life

72 hours

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
SRT prediction
Tidsramme: 72 hours

Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS

72 hours
Compare prSo2 & lung ultrasound between groups
Tidsramme: 72 hours

Determine correlation between prSO2 and lung ultrasound (LUS) scores between groups

72 hours
Compare prSo2 & OSI between groups
Tidsramme: 72 hours

Determine correlation between prSO2 and OSI between groups

72 hours
Compare prSo2 & SOPI between groups
Tidsramme: 72hrs

Determine correlation between prSO2 and SOPI between groups

72hrs

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
PRSO2/CUS
Tidsramme: 72hours

Determine the correlation between prSO2 and cerebral oxygenation (crSO2) between groups

72hours
Longitudinal analysis SOPI
Tidsramme: 72 hours

longitudinal comparison of SOPI between groups

72 hours
Longitudinal OSI
Tidsramme: 72 hours

longitudinal comparison of OSI between groups

72 hours
Longitudinal thoracic fluid content (TFC)
Tidsramme: 72 hours

longitudinal comparison of TFC between groups

72 hours
Longitudinal CI
Tidsramme: 72 hours

longitudinal comparison of cardiac index between groups

72 hours

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

30. desember 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

13. mai 2026

Først innsendt som oppfylte QC-kriteriene

17. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Patient data, as per SUN HREC guidelines, can only be shared upon an agreed upon data sharing agreement

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere